SHANGHAI, Oct. 4, 2019 /PRNewswire/ -- I-Mab Biopharma ("I-Mab"), a China and U.S.-based clinical stage biopharmaceutical company exclusively focused on the discovery and development of novel or ...
-
-
Recent Updates
- Shiseido Advances Hair Regeneration Push in China through Hainan Medical Zone
- Fung Group and Caohejing Chart New China Pathways for Global Expansion
- Novartis and Eastern Air Logistics Explore New Drug Supply Chain Paths in China
- China delivers second domestically built large cruise ship in Shanghai
- China’s Market Rout Tests Beijing as Stimulus Hopes Fade
- China Clean Tech Exports Redraw the Climate Fight for Developing Nations
- China Business Brief: Univest Securities Says NetClass Technology Completed $1.2 Million Nasdaq Offering
- GL Capital and Zylox Tonbridge Back Lifetech to Build China Vascular Device Platform
- Nvidia Tightens Cloud Rules as China AI Chip Markups Surge
- Europe Must Get Tougher with China to Avoid Trade Backlash, Pascal Lamy Says
Blogroll